The advent of a “noninvasive” device that can measure blood glucose for diabetes with no need to poke the skin and draw blood has been the dream for decades.
After all, why wouldn’t people with diabetes (PWDs) flock to a skin patch that can detect blood sugar levels through sweat, or contact lenses that use optical sensors to continuously beam glucose data directly to an app?
Numerous companies are pushing forward in this noninvasive continuous glucose monitoring (CGM) space, even in the midst of a global pandemic.
To date, it’s all been hype versus hope, as attempts to create those products have mostly fallen flat.
But industry analysts are predicting a booming market for noninvasive glucose monitoring technology by 2027.
Analysts note that there are systems under development for both home use and in-clinic and hospital settings. The former are wearables, and the latter will be non-wearable or tabletop systems.
They segment the systems under development by the type of technology used to take blood glucose readings — mainly, different types of spectroscopy, a technique that identifies chemicals based on the interaction of molecules with electromagnetic radiation.
Spectroscopy, which uses lasers that don’t pierce the skin, has been under study for decades. Researchers at MIT and elsewhere are finding that when used properly, it can produce highly accurate continuous data on blood glucose levels.
“Noninvasive still has a lot of challenges,” said Dr. Barry Ginsberg, who runs Diabetes Technology Consultants and is considered a premier expert on noninvasive diabetes tech after analyzing this trend for more than a decade.
Let’s take a look at some companies making progress.
SugarBEAT, from U.K.-based Nemaura Medical, is already approved for use in Europe. It’s a small peel-and-place patch that sticks onto your skin for 24 hours before needing replacement. The adhesive-backed rectangular transmitter sends wireless readings to a companion smartphone app via Bluetooth every 5 minutes.
According to the company, it works by “passing a mild, non-perceptible electric current across the skin, (which) draws a small amount of selected molecules, such as glucose, into a patch placed on the skin. These molecules are drawn out of the interstitial fluid which naturally sits just below the top layer of skin.”
Nemaura had originally submitted this to the Food and Drug Administration (FDA) in mid-2019, but the company had to refile the following year with additional study data. Then, the pandemic began. The company tells DiabetesMine they hope to continue conversations with regulators ASAP in 2021 in order to move forward.
In the meantime, they’re launching a nonregulated program called proBEAT in the United States, which is a professional CGM version developed for use in those with type 2 diabetes and others who don’t need continuous glucose data. Their program incorporates the device into a meal replacement plan, originally developed by the Joslin Diabetes Center in Boston.
Out of Germany, DiaMonTech has developed a system that uses molecular spectroscopy — the study of the absorption of light by molecules — to detect glucose molecules through the skin. They’re currently working on three versions:
- a phone-like “D-Pocket” handheld receiver that you press your finger on to get a glucose reading, which is expected in 2022–2023
- a small “D-sensor” embedded into watches or fitness bands, which is anticipated for 2024
- a more stationary, shoebox-sized device that would sit on a table and could be used in clinical settings, which is ready for use now
“Finger pricking is messy and inconvenient, and that’s why so many diabetics are not measuring enough to successfully manage their blood sugar,” DiaMonTech CEO Thorsten Lubinski told DiabetesMine. “Noninvasive measurements lower this hurdle, as measuring your blood sugar is as easy as using the fingerprint sensor on your mobile phone.”
Lubinski recognizes that others before have failed to develop noninvasive D-tech, but emphasizes that his company’s technology is more accurate and focuses specifically on the glucose molecule itself (rather than other things).
Created by startup co-founder Dr. Werner Mäntele, this technology has shown in research from 2020 that it has comparable accuracy to the minimally invasive FreeStyle Libre Flash glucose monitor from Abbott Diabetes.
This Dutch startup is working on a glucose sensor that is placed under the lower eyelid, from where it can wirelessly send glucose measurements directly to a smartphone.
The NovioSense device consists of a flexible metal coil just 2 centimeters long that contains nanosensors inside. The coil is covered by a protective layer of soft hydrogel, and it could measure constant changes in glucose levels from tear fluid using the same enzyme technology employed in conventional glucose test strips.
Clinical trial research published in late 2020 shows promising results for the technology and accuracy similar to the FreeStyle Libre, but there are few details and the company’s website has since disappeared.
This Silicon Valley-based startup is developing a noninvasive wearable wristwatch called LifeLeaf. The company says it can detect blood glucose levels, blood pressure, heart rate, sleep apnea, and more by using sensors already on the market and an additional light sensor to enhance accuracy.
According to this demo presentation at DiabetesMine’s D-Data ExChange forum in June 2020, it uses a “novel approach based on spectroscopic principles… to determine an accurate spectral signature for glucose.”
Their phase 1 product is aimed at consumers and people with prediabetes, and phase 2 will be for type 2 PWDs and eventually also those with type 1, with high and low alerts and guidance.
The company has conducted clinical trials around the world, and at last count, was aiming for FDA clearance by June 2021.
Out of Wales, a startup called Afon Technology is developing a sensor that would fit inside a smartwatch band to monitor glucose levels. Per the company’s website, it will provide real-time data and alert PWDs to high and low sugars, as well as track other health data. The company is working on clinical trials outside the United States, with plans for a launch starting in mid-2022.
Afon shares feedback from Dr. Hans de Vries, medical director at diabetes research organization Profil in Germany and a principal investigator at the University of Amsterdam’s Faculty of Medicine, who says: “We evaluated the Afon device under both hyper- and hypoglycemic conditions during the clinical trials and we were surprised and excited by the possibilities of this technology.”
Apple and Samsung
Both Apple and Samsung are rumored to be developing noninvasive CGM sensors of their own.
In fact, for years, many have confused the Apple Watch’s capability to display Dexcom’s CGM data with the notion that Apple itself offers CGM technology. But that buzz may finally be coming true soon.
According to a January 2021 report, Apple may be working on their own glucose monitoring tech that would use an integrated optical glucose sensor. The report has some fascinating visuals on what the Apple Watch display could look like.
Samsung may have its sights on this tech, too. This January 2021 news report states:
“Samsung Electronics will be equipped with a blood glucose measurement function in the new smart watch ‘Galaxy Watch 4’ (tentative name) to be introduced in the second half of this year. It is a no-blood sampling method that detects the level of glucose in the blood without blood collection using an optical sensor, and is expected to contribute to the health management of the general public as well as diabetics.”
There had been talk years back about a Samsung and Medtronic Diabetes partnership aimed at integrating glucose data into Android watches, but that relationship faded without any product materializing beyond prototypes.
There are numerous other small companies and universities currently working on noninvasive glucose monitoring technology, too. Several can be found at this list of at least 39 companies developing new CGM sensors.
DiabetesMine has been covering attempts at noninvasive diabetes tech since 2005, and a couple of the gadgets that captured headlines at the time remain legendary.
The first and best-known example is the infamous
Google and Novartis were once developing a contact lens that could use fluorescent light to monitor sugars through the eye, but that research was eventually scrapped because the company determined it wouldn’t work. That hasn’t stopped others from pursuing that same path in recent years.
Another notable name in noninvasive CGM tech for several years was C-8 MediSensors based in San Jose, California. This gadget promised to use light to identify and analyze glucose molecules under the skin via interstitial fluid, just like other traditional CGMs.
That company even obtained European CE Mark approval in 2012, but it never materialized and, eventually, the company went under a year later without any cash. Many of the C-8 scientists moved on to other companies like Apple and Google, before the company eventually rebranded and re-launched as C-Eight without any focus on noninvasive glucose monitoring.
Some industry experts who’ve watched this field for many years still insist that it will never happen.
“It’s the easiest slide-deck pitch to make, but it never seems to go anywhere,” said JDRF CEO Dr. Aaron Kowalski, who has been knee-deep in the world of emerging diabetes technology for decades. “There are major technology challenges that are so big, and you have to wonder if there is even a need anymore with what we have in diabetes technology today.”
Ginsberg at Diabetes Technology Consultants agrees. He predicts the market will be dominated by products that are simply “less invasive” and smaller than what we have now, such as the Dexcom G7 model expected in 2022.
Semi-retired industry consultant John L. Smith is another of the foremost experts on this front, author of the seminal paper “The Pursuit of Noninvasive Glucose: Hunting the Deceitful Turkey” article first published in 2006 and last updated in a 2020 seventh edition.
He writes that one of the most disturbing aspects in this field has been the “perennial” announcements by young companies that believe they’ve reached a solution for PWDs to no longer have to stick their fingers. Without exception, Smith says these announcements have been premature and are meant to generate hype, raising false hopes.
He estimates that it would take a minimum of 5 years and $25–$30 million in funding just to get a product to market, so it’s no wonder that most have pretty much failed to date.
He points to the wearables technology trend in recent years as growing strong beyond diabetes, but notes that the economic impact of the COVID-19 pandemic will likely push out many wannabe noninvasive tech developers.
Diabetes industry analyst David Kliff, an insulin-using PWD himself and notorious devil’s advocate, has maintained longstanding skepticism over noninvasive tech during his 20-plus years of writing for Diabetic Investor.
“It’s one of the better scams I’ve ever seen in the diabetes world,” he told DiabetesMine. “It sounds so appealing with all kinds of ‘Star Trek’-y elements. They sell the hype and there’s just enough science to back it up so it looks great. The mainstream media give it more play and people buy the dream.”
Kliff decries the millions of dollars that investors are tempted to “throw at this tech.”
The base problem, he says, is not so much having an easier way to get a glucose reading, but knowing what to do with that reading in order to improve your health outcomes.
“I’ve contended from day one, that whether it’s invasive or not, if the person doesn’t understand the number, it doesn’t matter if it’s given to them by God. I’m more impressed with practical technology that works and you can trust. For any patient, that’s the bottom line.”
Nevertheless, researcher John Smith writes about noninvasive glucose monitoring: “In spite of all the failures (and quite likely because I have been close to so many of them), it is still my fond wish that someday, somewhere, someone will find the solution to this intensely recalcitrant problem and realize the benefits for all people with diabetes worldwide.”